Isabel De Vleeschauwer

Title: Isabel De Vleeschauwer: Innovator in Vaccine Protection Assays

Introduction

Isabel De Vleeschauwer is a prominent inventor based in Rixensart, Belgium. She has made significant contributions to the field of vaccine protection assays, particularly in the area of Serum Bactericidal Activity (SBA) assays for Gram-negative bacteria. With a total of 3 patents to her name, her work has been instrumental in advancing the understanding and measurement of functional activity of serum antibodies against meningococcus.

Latest Patents

One of her latest patents focuses on the development of a vaccine protection assay. This invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram-negative bacteria. The SBA assay is recognized as the most important method for measuring the functional activity of serum antibodies against meningococcus. To determine whether a subject or a population is seropositive against invasive meningococcus, the SBA test must ideally be both sensitive and specific. Isabel and her team have discovered that the standard serotype A and W SBAs can be significantly improved in this regard.

Career Highlights

Isabel De Vleeschauwer works at GlaxoSmithKline Biologicals SA, where she continues to innovate and contribute to the field of vaccine research. Her expertise and dedication have positioned her as a key figure in the development of effective vaccine strategies.

Collaborations

Isabel collaborates with notable colleagues, including Nathalie Durant and Jan Poolman. Their combined efforts enhance the research and development of vaccine protection assays, furthering the impact of their work in the scientific community.

Conclusion

Isabel De Vleeschauwer's contributions to vaccine protection assays exemplify her commitment to advancing medical science. Her innovative patents and collaborative efforts continue to shape the future of vaccine research and development.